CNBX - Cannabics launches research program in melanoma treatment development push

Cannabics Pharmaceuticals ([[CNBX]]) announces the launch of a new research program for the development of a melanoma antitumor targeting medicine. Company highlights recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on melanoma cell lines.The update follows a previous development by the company of Cannabics RCC-33, a proprietary formula for the treatment of Colorectal Cancer, which showed a 33% reduction in tumor volume and a 35% increase in survival rate in recent in-vivo experiments in mice.The company plans to use new data to initiate in-vivo animal model studies to be included in a future product package that it intends to submit to the US FDA along with a Pre-IND Meeting request.

For further details see:

Cannabics launches research program in melanoma treatment development push